Theoretical · Grade C
KPV
KPV (Lys-Pro-Val, alpha-MSH Fragment 11-13)
Score
62 / 100
Origin
α-MSH fragment
Focus
Anti-inflammatory (gut)
Status
Investigational
TL;DR
01
A three-amino-acid peptide (Lys-Pro-Val) from the tail end of the hormone alpha-MSH, studied for its anti-inflammatory effects — especially in the gut.
02
In cells and in mouse models of colitis, it dampens key inflammatory signaling (NF-κB) and reduces gut inflammation, entering cells through the PepT1 transporter.
03
All of that evidence is preclinical; there are no human trials, which is why it is rated Theoretical.
04
Unlike its parent hormone, it does not darken skin, which is part of its appeal as an anti-inflammatory.
05
It is not approved anywhere and is sold as a research or compounded product with no purity or dosing guarantees.
Human trials
None
preclinical only
Models
Cell + mouse colitis
DSS/TNBS
Mechanism
NF-κB inhibition
via PepT1 uptake
Approval
None
research/compounded
Skin darkening
None
unlike parent α-MSH
Part 01 · How it works
Mechanism.
KPV is the small anti-inflammatory tail of alpha-MSH, a hormone with broad immune-calming effects. On its own, this tripeptide can slip into cells through a nutrient transporter (PepT1) that is abundant in the gut — and once inside, it quiets the master inflammatory switch (NF-κB) and lowers production of inflammatory messengers. In mice with induced colitis, oral KPV reduces inflammation. It's a clean, plausible story — but it stops at animals; no one has yet shown it helps people.
The calming 'tail' of a bigger hormone, small enough to sneak into gut cells and turn down the inflammation dial — demonstrated in mice, not yet in humans.
α-MSH C-terminus
KPV is the C-terminal tripeptide of alpha-MSH, retaining anti-inflammatory activity without melanocortin/pigmentation effects.
PepT1-mediated uptake
Transported into intestinal epithelial and immune cells by PepT1 (upregulated in IBD), concentrating its effect in inflamed gut.
NF-κB / MAPK inhibition
Suppresses NF-κB and MAP-kinase signaling, lowering pro-inflammatory cytokine output in cell models.
Evidence stage
Cell and mouse colitis models; no human trials.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for KPV. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Wk 1
200 mcg/day
Assess tolerance
TARGET
Wk 2–8
500 mcg–1 mg/day
Higher end for active gut inflammation
·
Oral is the most-cited route for gut targets because PepT1 uptake is upregulated in inflamed intestinal tissue, creating a self-targeting effect (Dalmasso 2008).
·
Preclinical anti-inflammatory activity was at nanomolar concentrations — not directly translatable to a consumer mcg dose.
·
C-terminal α-MSH(11-13) fragment; no FDA approval and no human efficacy data — oral/topical/injectable products are unregulated.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
GI tolerance (oral)
Generally reported as mild; uncharacterized in trials.
Anecdotal
Injection-site reactions
For injectable forms; no controlled data.
Anecdotal
Serious · rare
Long-term human safety
No human safety dataset.
Unknown
Immune modulation
As an immune-calming agent, unstudied effects on host defense are possible.
Theoretical
Product-quality risk
Research/compounded supply may not match labeled purity or dose.
Source-dependent
Absolute · do not use
×
Active systemic infection (may suppress needed inflammatory response)
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to KPV, alpha-MSH fragments, or any component
Relative · discuss first
!
Pregnancy or breastfeeding — no data
!
Active infection — theoretical concern with an immune-calming agent
!
Immunosuppression — additive effects unstudied
!
Anyone expecting proven human benefit — no human trials exist
Interactions
Immunosuppressants (tacrolimus, cyclosporine, biologics)
Additive immunosuppressive/inflammation-modulating effects; may increase infection risk
Moderate
NSAIDs
Additive inflammation-modulating effects; generally favorable but monitor for excessive immune suppression in vulnerable patients
Minor
TNF inhibitors (adalimumab, infliximab)
KPV inhibits NF-kB and TNF pathways; additive immunosuppression risk
Moderate
Labs to monitor
CRP / ESR
Baseline and monthly
Track inflammatory markers (primary indication is inflammation-modulating)
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CBC with Differential
Baseline and every 3 months
Monitor immune parameters
Fecal Calprotectin
Baseline and monthly
If used for GI inflammation/IBD
Part 04 · Evidence
How strong is the evidence?
62
Grade C
Grade C, Theoretical. KPV has a clean, well-characterized anti-inflammatory mechanism and encouraging mouse-colitis data, but no human trials at all. It is a promising preclinical candidate, not a demonstrated therapy.
Mechanistic plausibility
Well-defined PepT1 uptake and NF-κB inhibition; derived from a hormone with real anti-inflammatory biology.
78
Human evidence
No human trials of any phase.
32
Safety & tolerability
No serious signals in preclinical work; human safety uncharacterized.
66
Durability
No human outcome or durability data.
55
Independence
Studied by more than one academic group in the IBD context, a modest plus.
64
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2008
Gastroenterology Flagged
PepT1-mediated KPV uptake reduces intestinal inflammation
Nanomolar KPV inhibited NF-κB and MAPK signaling and reduced pro-inflammatory cytokines; oral KPV reduced colitis severity in two mouse models via PepT1 uptake.
Human cell lines + mouse DSS/TNBS colitis models · Strong mechanism paper, but entirely cell/animal.
PMID 18061177 ↗
High (preclinical)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
No human trials — encouraging mice, untested people
Mechanism limit Gastroenterology · 2008
KPV's anti-inflammatory and anti-colitis effects are established only in cell lines and mouse models. No human trial has evaluated it for inflammatory bowel disease or any other condition.
What this means: The preclinical case is genuinely promising, but promising in mice is where many anti-inflammatory candidates stall. Treat human benefit as unproven.
PMID 18061177 ↗
02
Delivery and stability of a free tripeptide are open questions
Mechanism limit Gastroenterology · 2008
KPV's demonstrated effect depends on PepT1-mediated uptake and, in later work, targeted delivery; the pharmacokinetics, stability, and effective dosing of plain KPV in humans are not established.
What this means: Even if the biology holds in humans, getting an active dose to the right tissue is an unsolved problem the marketed product does not address.
PMID 18061177 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Not approved
No approved product; sold as a research chemical or compounded. No legal consumer medicine.
Grey-market/compounded; unregulated
European Union
Not approved
No approved product.
N/A
United Kingdom
Not approved
No approved product.
N/A
Canada
Not approved
No approved product.
N/A
The Peptide Column takes no affiliate commission from any source. KPV is not approved as a medicine anywhere; material sold to individuals is research-grade or compounded and unregulated for human use, and its benefits are unproven in people. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Is KPV appropriate for my inflammatory condition given the limited human data?
02
What is the difference between oral, topical, and injectable KPV?
03
How does KPV compare to established inflammation-modulating treatments for my condition?
04
Are there any drug interactions I should be aware of with KPV?
05
What would a reasonable trial period look like to evaluate KPV's effects?
06
Is there clinical trial data in humans supporting KPV for gut inflammation?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. PepT1-mediated KPV uptake reduces intestinal inflammation · Gastroenterology, 2008 · PMID 18061177 ↗
- 02. PubMed. KPV / PepT1 anti-inflammatory literature (preclinical)